Specifically, the detection of glypican-1-positive EVs has demonstrated an area under the curve (AUC) of 1.0 for identifying early-stage pancreatic cancer, significantly outperforming conventional serum markers [112]. This evidence concerns the gene GPC1 and pancreatic neoplasm.